Charles J Sherr

List of Publications by Year
in descending order

173 papers	44,354 citations	10389 72 h-index	5829 161 g-index
175 all docs	175 docs citations	175 times ranked	29559 citing authors

#	Article	IF	Citations
1	CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development, 1999, 13, 1501-1512.	5.9	5,227
2	Cancer Cell Cycles. Science, 1996, 274, 1672-1677.	12.6	4,932
3	G1 phase progression: Cycling on cue. Cell, 1994, 79, 551-555.	28.9	2,668
4	Mammalian G1 cyclins. Cell, 1993, 73, 1059-1065.	28.9	1,994
5	The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1. Cell, 1985, 41, 665-676.	28.9	1,602
6	Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19. Cell, 1997, 91, 649-659.	28.9	1,519
7	The RB and p53 pathways in cancer. Cancer Cell, 2002, 2, 103-112.	16.8	1,473
8	Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 1995, 83, 993-1000.	28.9	1,393
9	Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell, 1991, 65, 701-713.	28.9	1,179
10	Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 1993, 73, 487-497.	28.9	1,056
11	Living with or without cyclins and cyclin-dependent kinases. Genes and Development, 2004, 18, 2699-2711.	5.9	945
12	D-type cyclins. Trends in Biochemical Sciences, 1995, 20, 187-190.	7.5	905
13	The INK4a/ARF network in tumour suppression. Nature Reviews Molecular Cell Biology, 2001, 2, 731-737.	37.0	890
14	Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell, 1992, 71, 323-334.	28.9	888
15	Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biology, 1999, 1, 20-26.	10.3	854
16	Principles of Tumor Suppression. Cell, 2004, 116, 235-246.	28.9	850
17	Forging a signature of in vivo senescence. Nature Reviews Cancer, 2015, 15, 397-408.	28.4	775
18	Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell, 1994, 79, 487-496.	28.9	741

#	Article	IF	Citations
19	Cellular Senescence. Cell, 2000, 102, 407-410.	28.9	720
20	Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discovery, 2016, 6, 353-367.	9.4	717
21	Tumor suppression by Ink4aâ€“Arf: progress and puzzles. Current Opinion in Genetics and Development, 2003, 13, 77-83.	3.3	666
22	Tumor surveillance via the ARFâ€“p53 pathway. Genes and Development, 1998, 12, 2984-2991.	5.9	641
23	The ARF/p53 pathway. Current Opinion in Genetics and Development, 2000, 10, 94-99.	3.3	612
24	Divorcing ARF and p53: an unsettled case. Nature Reviews Cancer, 2006, 6, 663-673.	28.4	535
25	Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene, 1997, 15, 203-211.	5.9	527
26	Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature, 1987, 325, 549-552.	27.8	370
27	Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23. Molecular and Cellular Biology, 2004, 24, 985-996.	2.3	351
28	p53-independent functions of the p19ARF tumor suppressor. Genes and Development, 2000, 14, 2358-2365.	5.9	317
29	Infectious C-type virus isolated from a baboon placenta. Nature, 1974, 248, 17-20.	27.8	301
30	Nucleolar Arf Tumor Suppressor Inhibits Ribosomal RNA Processing. Molecular Cell, 2003, 11, 415-424.	9.7	267
31	NK cellâ€“mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science, 2018, 362, 1416-1422.	12.6	267
32	Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex. Molecular and Cellular Biology, 2000, 20, 2517-2528.	2.3	260
33	A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene) Tj ETQq1 1 0.784314 rgBT /Overlo	28.9	257
34	Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics, 1992, 13, 565-574.	2.9	246
35	Nucleotide sequences of feline retroviral oncogenes (v-fes) provide evidence for a family of tyrosine-specific protein kinase genes. Cell, 1982, 30, 775-785.	28.9	217
36	Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell, 2020, 181, 424-441.e21.	28.9	216

#	Article	IF	Citations
37	Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6688-6693.	7.1	182
38	Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5qâ^' syndrome. Cell, 1985, 42, 421-428.	28.9	181
39	N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes and Development, 2004, 18, 1862-1874.	5.9	180
40	Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. Cell, 1988, 55, 655-661.	28.9	175
41	Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature, 1991, 353, 361-363.	27.8	171
42	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes and Development, 2014, 28, 1800-1814.	5.9	167
43	Cytokine-dependent imatinib resistance in mouse BCR-ABL⁺, Arf-null lymphoblastic leukemia. Genes and Development, 2007, 21, 2283-2287.	5.9	166
44	Gene Expression and Cell Cycle Arrest Mediated by Transcription Factor DMP1 Is Antagonized by D-Type Cyclins through a Cyclin-Dependent-Kinase-Independent Mechanism. Molecular and Cellular Biology, 1998, 18, 1590-1600.	2.3	158
45	Characterization of a type C virus released from the porcine cell line PK(15). Virology, 1974, 58, 65-74.	2.4	144
46	Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15930-15935.	7.1	139
47	The ins and outs of RB: coupling gene expression to the cell cycle clock. Trends in Cell Biology, 1994, 4, 15-18.	7.9	135
48	The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes and Development, 2005, 19, 2656-2667.	5.9	133
49	INK4d-Deficient Mice Are Fertile Despite Testicular Atrophy. Molecular and Cellular Biology, 2000, 20, 372-378.	2.3	129
50	The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line. Nature, 1986, 324, 377-380.	27.8	117
51	Phosphorylation of murine type C viral p12 proteins regulates their extent of binding to the homologous viral RNA. Cell, 1977, 10, 487-496.	28.9	113
52	Ras-Raf-Arf Signaling Critically Depends on the Dmp1 Transcription Factor. Molecular and Cellular Biology, 2005, 25, 220-232.	2.3	109
53	Sumoylation induced by the Arf tumor suppressor: A p53-independent function. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7689-7694.	7.1	107
54	Control of Spermatogenesis in Mice by the Cyclin D-Dependent Kinase Inhibitors p18 Ink4c and p19 Ink4d. Molecular and Cellular Biology, 2001, 21, 3244-3255.	2.3	103

#	Article	IF	Citations
55	Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes and Development, 2001, 15, 2934-2939.	5.9	101
56	Infectious primate type C viruses: Three isolates belonging to a new subgroup from the brains of normal gibbons. Virology, 1975, 67, 335-343.	2.4	99
57	S-tropic murine type-C viruses: Frequency of isolation from continuous cell lines, leukemia virus preparations and normal spleens. International Journal of Cancer, 1974, 13, 587-598.	5.1	95
58	Specific binding of the type C viral core protein p12 with purified viral RNA. Cell, 1976, 7, 21-32.	28.9	95
59	Transmembrane orientation of glycoproteins encoded by the v-fms oncogene. Cell, 1985, 40, 971-981.	28.9	95
60	Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53-Dependent and Independent Activities of the Arf Tumor Suppressor Protein. Cell Cycle, 2005, 4, 1593-1598.	2.6	95
61	A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene, 1999, 18, 573-582.	5.9	94
62	Arf induces p53-dependent and -independent antiproliferative genes. Cancer Research, 2003, 63, 1046-53.	0.9	92
63	Myc-Mediated Proliferation and Lymphomagenesis, but Not Apoptosis, Are Compromised by E2f1 Loss. Molecular Cell, 2003, 11, 905-914.	9.7	91
64	Biologic and immunologic properties of porcine type C viruses. Virology, 1975, 66, 616-619.	2.4	90
65	Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes and Development, 2000, 14, 1797-1809.	5.9	89
66	Isolation and characterization of a new type D retrovirus from the Asian primate, Presbytis obscurus (spectacled langur). Virology, 1978, 84, 189-194.	2.4	88
67	Cell Cycleâ€“Targeted Cancer Therapies. Annual Review of Cancer Biology, 2017, 1, 41-57.	4.5	88
68	Atoh1 Inhibits Neuronal Differentiation and Collaborates with Gli1 to Generate Medulloblastoma-Initiating Cells. Cancer Research, 2010, 70, 5618-5627.	0.9	87
69	Radioimmunoassay of the major group specific protein of endogenous baboon type C viruses: Relation to the RD-114/CCC group and detection of antigen in normal baboon tissues. Virology, 1974, 61, 168-181.	2.4	85
70	Ink4aâ€Arf locus in cancer and aging. Wiley Interdisciplinary Reviews: Developmental Biology, 2012, 1, 731-741.	5.9	85
71	Failure of CDKN2A/B (INK4A/Bâ€“ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes and Development, 2008, 22, 1411-1415.	5.9	84
72	Baboons and their close relatives are unusual among primates in their ability to release nondefective endogenous type C viruses. Virology, 1976, 72, 278-282.	2.4	81

#	Article	IF	Citations
73	MAC-1, a new genetically transmitted type C virus of primates: â€œlow frequencyâ€•activation from stumptail monkey cell cultures. Cell, 1978, 13, 775-782.	28.9	77
74	Endogenous baboon type C virus (M7): Biochemical and immunologic characterization. Virology, 1974, 58, 492-503.	2.4	76
75	Multilineage hematopoietic disorders induced by transplantation of bone marrow cells expressing the v-fms oncogene. Cell, 1987, 51, 663-673.	28.9	74
76	Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood, 2011, 117, 3585-3595.	1.4	73
77	Tbx3, the ulnar-mammary syndrome gene, andTbx2interact in mammary gland development through a p19Arf/p53-independent pathway. Developmental Dynamics, 2005, 234, 922-933.	1.8	72
78	Parsing Ink4a/Arf. Cell, 2001, 106, 531-534.	28.9	69
79	N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11579-11583.	7.1	69
80	Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors. Cancer Research, 2007, 67, 2676-2684.	0.9	66
81	Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf. EMBO Journal, 2009, 28, 1904-1915.	7.8	66
82	Arf-induced turnover of the nucleolar nucleophosmin-associated SUMO-2/3 protease Senp3. Cell Cycle, 2008, 7, 3378-3387.	2.6	64
83	Mixed splenocyte cultures and graft versus host reactions selectively induce an â€œS-tropicâ€•murine type C virus. Cell, 1974, 1, 55-58.	28.9	63
84	Cyclin D- and E-Dependent Kinases and the p57^{KIP2} Inhibitor: Cooperative Interactions In Vivo. Molecular and Cellular Biology, 1999, 19, 353-363.	2.3	63
85	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Reports, 2017, 18, 2907-2917.	6.4	61
86	Oncogenic Ras Induces p19ARF and Growth Arrest in Mouse Embryo Fibroblasts Lacking p21Cip1 and p27Kip1 without Activating Cyclin D-dependent Kinases. Journal of Biological Chemistry, 2000, 275, 27473-27480.	3.4	60
87	The RING domain of Mdm2 can inhibit cell proliferation. Cancer Research, 2002, 62, 1222-30.	0.9	59
88	Molecular Cloning, Expression Pattern, and Chromosomal Localization of Human CDKN2D/INK4d,an Inhibitor of Cyclin D-Dependent Kinases. Genomics, 1995, 29, 623-630.	2.9	58
89	A gene (Bevi) on human chromosome 6 is an integration site for baboon type C DNA provirus in human cells. Cell, 1978, 14, 995-1005.	28.9	57
90	Two Tumor Suppressors, p27Kip1 and Patched-1, Collaborate to Prevent Medulloblastoma. Molecular Cancer Research, 2009, 7, 33-40.	3.4	55

#	Article	IF	Citations
91	Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice. Cancer Research, 2003, 63, 5420-7.	0.9	55
92	Colony-stimulating factor-1 receptor (c-fms). Journal of Cellular Biochemistry, 1988, 38, 179-187.	2.6	51
93	Isolation of type-c viruses from the asian feral mousemus musculus molossinus. International Journal of Cancer, 1975, 15, 211-220.	5.1	50
94	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin Dâ€“Dependent Kinases. Blood, 1997, 90, 126-137.	1.4	48
95	IMMUNOGLOBULIN SYNTHESIS AND SECRETION. Journal of Experimental Medicine, 1971, 133, 901-920.	8.5	47
96	A new class of murine retroviruses: Immunological and biochemical comparison of novel isolates from Mus cervicolor and Mus caroli. Virology, 1977, 80, 401-416.	2.4	45
97	Antibodies to distal carboxyl terminal epitopes in the v-fms-coded glycoprotein do not cross-react with the c-fms gene product. Virology, 1986, 152, 432-445.	2.4	45
98	CELL SURFACE IMMUNOGLOBULIN. Journal of Experimental Medicine, 1972, 135, 1392-1405.	8.5	44
99	A new genetic locus, bevi, on human chromosome 6 which controls the replication of baboon type C virus in human cells. Cell, 1977, 12, 251-262.	28.9	40
100	Regulation of the CD13/Aminopeptidase N Gene by DMP1, a Transcription Factor Antagonized by D-Type Cyclins. Journal of Biological Chemistry, 1998, 273, 29188-29194.	3.4	40
101	Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6285-6290.	7.1	40
102	p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia. Neoplasia, 1999, 1, 253-261.	5.3	37
103	Mutant Feline Sarcoma Proviruses Containing the Viral Oncogene (v- fes) and Either Feline or Murine Control Elements. Journal of Virology, 1983, 45, 1004-1016.	3.4	37
104	Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). Gene, 1999, 229, 223-228.	2.2	36
105	Antagonism of Myc functions by Arf. Cancer Cell, 2004, 6, 309-311.	16.8	36
106	A New Cell-Cycle Target in Cancer â€” Inhibiting Cyclin Dâ€“Dependent Kinases 4 and 6. New England Journal of Medicine, 2016, 375, 1920-1923.	27.0	36
107	Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood, 2015, 125, 1444-1451.	1.4	35
108	SYNTHESIS AND INTRACELLULAR TRANSPORT OF IMMUNOGLOBULIN IN SECRETORY AND NONSECRETORY CELLS *. Annals of the New York Academy of Sciences, 1971, 190, 250-267.	3.8	34

#	Article	IF	Citations
109	The CDK Inhibitor p18Ink4c is a Tumor Suppressor in Medulloblastoma. Cell Cycle, 2006, 5, 363-365.	2.6	32
110	The Mononuclear Phagocyte Colony-Stimulating Factor (CSF-1, M-CSF). Hematology/Oncology Clinics of North America, 1989, 3, 479-493.	2.2	31
111	The colony-stimulating factor 1 (CSF-1) receptor (c-fms protooncogene product) and its ligand. Journal of Cell Science, 1988, 1988, 27-44.	2.0	30
112	Hzf , a p53-Responsive Gene, Regulates Maintenance of the G 2 Phase Checkpoint Induced by DNA Damage. Molecular and Cellular Biology, 2006, 26, 502-512.	2.3	30
113	Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood, 2011, 117, 5453-5462.	1.4	30
114	Erk2 Signaling and Early Embryo Stem Cell Self-Renewal. Cell Cycle, 2004, 3, 239-241.	2.6	29
115	Monoclonal Antibodies to Mammalian D-Type G1 Cyclins. Hybridoma, 1994, 13, 37-44.	0.6	28
116	The fms oncogene. Biochimica Et Biophysica Acta: Reviews on Cancer, 1988, 948, 225-243.	7.4	27
117	Bared essentials of CDK2 and cyclin E. Nature Genetics, 2003, 35, 8-9.	21.4	27
118	Expression of Arf Tumor Suppressor in Spermatogonia Facilitates Meiotic Progression in Male Germ Cells. PLoS Genetics, 2011, 7, e1002157.	3.5	27
119	Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1112-21.	7.1	27
120	Monoclonal Antibodies to the Mouse p19ArfTumor Suppressor Protein. Hybridoma, 2004, 23, 293-300.	0.4	26
121	Simultaneous Gene Editing by Injection of mRNAs Encoding Transcription Activator-Like Effector Nucleases into Mouse Zygotes. Molecular and Cellular Biology, 2014, 34, 1649-1658.	2.3	26
122	D1 in G2. Cell Cycle, 2002, 1, 32-34.	2.6	23
123	Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. Blood, 2009, 114, 4451-4459.	1.4	23
124	Regulation of mononuclear phagocyte proliferation by colony-stimulating factor-1. International Journal of Cell Cloning, 1990, 8, 46-62.	1.6	22
125	Hzf regulates adipogenesis through translational control of C/EBPÎ±. EMBO Journal, 2008, 27, 1481-90.	7.8	22
126	Autophagy by ARF: A Short Story. Molecular Cell, 2006, 22, 436-437.	9.7	20

#	Article	IF	Citations
127	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin Dâ€“Dependent Kinases. Blood, 1997, 90, 126-137.	1.4	19
128	N-Terminal Polyubiquitination of the ARF Tumor Suppressor, A Natural Lysine-Less Protein. Cell Cycle, 2004, 3, 1367-1369.	2.6	18
129	Regulation of the Arf tumor suppressor in EÎ¼-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis. Blood, 2007, 109, 792-794.	1.4	17
130	Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Scientific Reports, 2018, 8, 8733.	3.3	17
131	Differential post-transcriptional regulation of two Ink4 proteins, p18Ink4c and p19Ink4d. Cell Cycle, 2008, 7, 3737-3746.	2.6	16
132	Isolation of a type C virus (FS-1) from the European wildcat (Felis sylvestris). Virology, 1975, 66, 117-127.	2.4	15
133	Transplantable murine tumors release mouse-tropic and xenotropic type-c viruses. International Journal of Cancer, 1975, 15, 555-560.	5.1	14
134	Oncogenic Potential of the c-FMS Proto-Oncogene (CSF-1 Receptor). Cell Cycle, 2003, 2, 5-6.	2.6	14
135	The Arf Tumor Suppressor in Acute Leukemias: Insights from Mouse Models of Bcrâ€“Abl-Induced Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 2007, 604, 107-114.	1.6	13
136	Developmentally Restricted Protection From Notch1-Induced T Cell Acute Lymphoblastic Leukemia by the Arf Tumor Suppressor.. Blood, 2009, 114, 143-143.	1.4	13
137	Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia. Experimental Hematology, 2013, 41, 377-386.	0.4	12
138	[35] Purification and assay of murine leukemia viruses. Methods in Enzymology, 1979, 58, 412-424.	1.0	11
139	Regulation of CYL /Cyclin D Genes by Colonyâ€Stimulating Factor 1. Novartis Foundation Symposium, 1992, 170, 209-219.	1.1	11
140	Editorial overview checks and balances. Current Opinion in Cell Biology, 1994, 6, 833-835.	5.4	10
141	Endogenous feline (RD-114) and baboon type C viruses have related specific RNA-binding proteins and genome binding sites. Virology, 1978, 84, 99-107.	2.4	9
142	BCRâ€“ABL and CDKN2A: a dropped connection. Nature Reviews Cancer, 2008, 8, 563-563.	28.4	9
143	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenetics and Genomics, 2014, 24, 263-271.	1.5	9
144	Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of Arf tumor suppressor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7420-7425.	7.1	9

#	Article	IF	Citations
145	Developmental strategies for evasion ofArftumor suppression. Cell Cycle, 2010, 9, 14-15.	2.6	8
146	Surprising regulation of cell cycle entry. Science, 2019, 366, 1315-1316.	12.6	8
147	INTERSPECIES TRANSFER OF RNA TUMOR VIRUS GENES: IMPLICATIONS FOR THE SEARCH FOR â€œHUMANâ€•TYPE C VIRUSES. , 1976, , 369-384.		7
148	Polymorphic control of subunit synthesis for the enzyme lactate dehydrogenase in the newt,Triturus viridescens. The Journal of Experimental Zoology, 1968, 169, 287-292.	1.4	6
149	Transformation by the v-fms oncogene product: An analog of the CSF-1 receptor. Journal of Cellular Biochemistry, 1987, 33, 109-115.	2.6	6
150	The D-Type Cyclins: A Historical Perspective. Current Cancer Research, 2018, , 1-26.	0.2	5
151	Preparation of rat monoclonal antibodies to epitopes encoded by the viral oncogene (v-fms) of McDonough feline sarcoma virus. Journal of Cellular Biochemistry, 1982, 19, 275-280.	2.6	4
152	Leukemia and lymphoma 1987. Cell, 1987, 48, 727-729.	28.9	4
153	Fibroblast and hematopoietic cell transformation by thefms oncogene (CSF-1 receptor). Journal of Cellular Physiology, 1987, 133, 83-87.	4.1	4
154	Expression arrays illuminate a way forward for mantle cell lymphoma. Cancer Cell, 2003, 3, 100-102.	16.8	4
155	AnArfGFP/GFPIndicator Mouse Reveals that theArfTumor Suppressor Monitors Latent Oncogenic Signals In Vivo. Cell Cycle, 2004, 3, 237-238.	2.6	4
156	The c-fms Proto-Oncogene and the CSF-1 Receptor. , 1986, , 93-99.		4
157	Acquired palbociclib resistance in KRAS-mutant lung cancer. Oncotarget, 2018, 9, 32734-32735.	1.8	3
158	Control of G1 Progression by Mammalian D-Type Cyclins. , 1994, , 17-23.		3
159	Functional Expression of the Human Receptor for Colony-Stimulating Factor 1 (CSF-1) in Hamster Fibroblasts: CSF-1 Stimulates Na+/H+exchange and DNA-Synthesis in the Absence of Phosphoinositide Breakdown. Growth Factors, 1990, 2, 289-300.	1.7	2
160	Infectious Primate Type C Virus Group: Evidence for an Origin from an Endogenous Virus of the Rodent, Mus caroli. Proceedings of the International Symposium on Comparative Leukemia Research, 1975, 43, 115-120.	0.1	1
161	Activation of endogenous type-C viral p30 antigen in chemically-induced rat hepatocellular carcinomas. International Journal of Cancer, 1978, 21, 756-761.	5.1	1
162	Inactivation of the Arf Tumor Suppressor in Mouse BCR-ABL(+) B Cells Greatly Increases the Frequency of Leukemia-Initiating Cells and Confers Imatinib Resistance In Vivo.. Blood, 2006, 108, 385-385.	1.4	1

#	Article	IF	Citations
163	For the public record: Status of oncogene research. BioEssays, 1984, 1, 133-135.	2.5	0
164	Transformation by feline retroviruses. , 1984, 26, 45-58.		0
165	Signalâ€Response Coupling Mediated by the Transduced Colonyâ€Stimulating Factorâ€1 Receptor and its Oncogenic fms Variants in Naive Cells. Novartis Foundation Symposium, 1990, 148, 96-109.	1.1	0
166	Abstract A253: Acquired Bcrâ€Abl kinase domain mutations are not responsible for persistence of dasatinibâ€refractory disease in murine Ph+ALL. , 2009, , .		0
167	How politics trumped peer review at Texas cancer institute. BMJ, The, 2012, 345, e7334-e7334.	6.0	0
168	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. Blood, 2012, 120, 3560-3560.	1.4	0
169	Prevention Of Minimal Residual Disease In Ph+ ALL. Blood, 2013, 122, 1265-1265.	1.4	0
170	Relationship of the c-fms Protooncogene Product to the CSF-1 Receptor. , 1987, , 81-91.		0
171	The Macrophage Colony Stimulating Factor, CSF-1, and Its Receptor (c-fms). , 1989, , 193-207.		0
172	Abstract IA21: Mitogenic signaling and the RB/p53 network. , 2016, , .		0
173	Sexually dimorphic tumor suppression by small mitochondrial Arf. Oncotarget, 2019, 10, 1235-1237.	1.8	0